Oral Testosterone Undecanoate
Jatenzo and Kyzatrex, Modern Oral TRT and the PRIME / Mangoceuticals DTC Channel
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Jatenzo FDA Approved 2019; Kyzatrex 2022
- WADA
- Prohibited (S1 Anabolic Agent)
Reference only. Not medical advice.
What can go wrong
Labeled risk of blood pressure elevation with consequent potential cardiovascular risk; absorption depends on food intake; twice-daily dosing burden; cost. As with all TRT, it is approved only for diagnosed hypogonadism, and DTC marketing may outpace appropriate diagnostic gatekeeping.
This is something to take to a clinician. The Atlas can tell you what is known about oral testosterone undecanoate in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Modern oral testosterone undecanoate (Jatenzo, FDA approved 2019; Kyzatrex, 2022) solved the historical problem of oral testosterone: older 17-alpha-alkylated oral androgens were hepatotoxic, so injectable and transdermal routes dominated. Undecanoate is absorbed via the intestinal lymphatics, bypassing first-pass liver metabolism and avoiding that toxicity. Taken twice daily with food, it offers no needles and no transfer risk. Its principal labeled hazard is blood pressure elevation, the FDA requires BP monitoring, and the products carry a warning that they may increase cardiovascular risk via raised BP. The direct-to-consumer oral category is exemplified by PRIME (Mangoceuticals, launched March 2024, powered by Kyzatrex).
The pill that finally avoided the liver, and traded that win for a blood-pressure warning.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Testosterone undecanoate is a fatty-acid ester absorbed preferentially into intestinal lymphatic vessels, bypassing the Atlas circulation and first-pass hepatic metabolism. This avoids the liver toxicity of older alkylated oral androgens while delivering testosterone systemically; food (dietary fat) is required for adequate absorption.
Why the liver problem moved to the blood pressure problem
The lymphatic absorption route is genuinely clever, it removes the hepatotoxicity that doomed earlier oral testosterone. But the modern oral products carry a distinct labeled risk: they can raise blood pressure, which in turn can increase cardiovascular risk. The FDA mandated blood pressure monitoring as a condition of use. In the DTC channel, products like PRIME (Mangoceuticals, powered by Kyzatrex) market oral convenience to a broad audience; the blood pressure warning and the requirement for genuine hypogonadism diagnosis are easy to under-emphasize in subscription-driven marketing.
Safety in detail
Oral testosterone undecanoate requires evaluation and ongoing monitoring by a qualified physician, including mandatory blood pressure monitoring per FDA labeling. It is approved only for hypogonadism from a medical condition; self-administration carries documented health risks.
Replacement is not the same as a cycle
Oral undecanoate is dosed for physiological replacement. As with any testosterone product, doses driving levels above the physiological range constitute supraphysiological use with the attendant erythrocytosis, cardiovascular, and HPG-suppression risks not contemplated by the labeled indication.
What it does to fertility
Like all exogenous testosterone, oral undecanoate suppresses LH/FSH and spermatogenesis and is contraindicated in men seeking fertility; the convenience of an oral product does not change this HPG suppression.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Blood pressure (FDA-required, baseline and periodic)
- Hematocrit
- Total testosterone (timing relative to dose matters)
- PSA per guideline
- Lipid panel
- Confirmation of hypogonadism diagnosis before initiation
What people get wrong
Often saidOral testosterone destroys your liver
ActuallyModern undecanoate (Jatenzo, Kyzatrex) bypasses the liver via lymphatic absorption; the old hepatotoxic alkylated orals are a different class. The modern risk is blood pressure, not the liver.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Jatenzo approval
- 2019
- Kyzatrex approval
- 2022
- Dosing
- Twice daily with food
- Key warning
- Blood pressure elevation
- DTC example
- PRIME by Mangoceuticals (2024)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Oral Testosterone Undecanoate. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Jatenzo pivotal trial / FDA approval2019
Demonstrated restoration of testosterone to physiological range; established BP-monitoring requirement
Kyzatrex FDA approval2022
Second modern oral testosterone undecanoate approved in the US